BAY 12 9566 IN COMBINATION W/ ETOPOSIDE & CARBOPLATIN IN CANCER PATIENTS

BAY 12-9566是一种基质金属蛋白酶抑制剂(MMPI)，最近在梅奥诊所进行了I期测试。它的主要作用是防止胶原基质的分解，从而防止癌症的扩散。在使用小鼠异种移植模型的临床前研究中，Bay 12-9566增加了依托泊苷的抗肿瘤作用。包括顺铂在内的其他抗肿瘤药物也有类似的活性。因此，本研究的目标是确定Bay12-9566/依托泊苷/卡铂的最大耐受量。一旦MTD被确定，这种组合将被用于肺癌的II期研究。在目前的研究中，将确定一组晚期癌症患者的耐受性、药代动力学和抗肿瘤活性，这些患者没有其他标准或潜在的治疗方法可用。将对接受Bay 12-9566/依托泊苷的患者和接受Bay 12-9566/依托泊苷/卡铂的患者进行药代动力学研究。每组共6名患者。

BAY 12-9566 is a matrix metalloproteinase inhibitor (MMPI) which has recently undergone phase I testing at the Mayo Clinic. Its primary action is to prevent the breakdown of the collagen matrix and thus prevent the spread of cancer. In preclinical studies using a mouse xenograft model BAY 12-9566 increased the antitumor effect of etoposide. Similar activity has been noted with other antineoplastic drugs including cisplatin. As such it is the goal of this study to determine the maximum tolerated dose of the combination of BAY 12-9566/etoposide/carboplatin. Once the MTD has been determined, this combination will then be used in a phase II study of lung cancer. In the present study, tolerability, pharmacokinetics, and antitumor activity will be determined in a group of patients with advanced cancer for whom no other standard or potentially curative treatments are available. Pharmacokinetics will be studied for patients' receiving BAY 12-9566/etoposide and for those receiving BAY 12-9566/etoposide/carboplatin. A total of 6 patients will be enrolled into each group.